Athenex Pharma Solutions, LLC, Clarence, NY
Is Athenex Pharma Solutions, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B, with FDA’s note “Out of business”.
Does Athenex Pharma Solutions, LLC hold a New York pharmacy license?
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. The Delaware Division of Professional Regulation also lists nonresident license AD-0000050 for Athenex Pharma Solutions, LLC, CLARENCE, NY, status Closed, as of Nov 10, 2026.
Has Athenex Pharma Solutions, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Feb 13, 2019) and 1 FMD-145 letter (Aug 10, 2021) for Athenex Pharma Solutions, LLC. State board actions: record found. The New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments lists “Application for consent order granted Penalty agreed upon $20,000 fine, 1 year probation” dated Feb 11, 2019, case Cal. No. 30733 on registration 035379.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Athenex Pharma Solutions, LLC
- Location
- Clarence, NY
- Type as FDA labels it
- 503B
- FDA’s note
- Out of business
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Sep 16, 2022
- FDA Data Dashboard inspections
- 4 inspections: 3 VAI, 1 NAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 6 observations
- State board records
- Not checked (license records); board actions matched: 1
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Athenex Pharma Solutions, LLC, a 503B facility, with 6 dated actions.
| Document | |||
|---|---|---|---|
| Sep 16, 2022 | Form 483 | 483 Issued 09/16/2022 | FDA copy (archived) |
| Aug 10, 2021 | FMD-145 letter | FMD-145 Letter Issued 08/10/2021 | Not linked by FDA |
| Aug 28, 2019 | Form 483 | 483 Issued 08/28/2019 | fda.gov |
| Aug 6, 2019 | Press release or statement | FDA Statement : FDA Statement on Court Ruling Related to Compounded Bulk Drug Substances and the Agency’s Ongoing Efforts to Implement its Compounding Authorities (08/06/2019) | FDA copy (archived) |
| Aug 2, 2019 | Press release or statement | Firm Press Release : Athenex Provides an Update Regarding the Vasopressin Case (08/02/2019) | FDA copy (archived) |
| Feb 13, 2019 | Untitled letter | Untitled Letter Issued 02/13/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Athenex Pharma Solutions, LLC, Clarence, NY (FEI number 3008876196), matched to this page by exact name, city and state. It lists 4 inspections: 3 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 16, 2022 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3008876196 | 1179659 |
| Aug 28, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3008876196 | 1100698 |
| Dec 13, 2017 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3008876196 | 1034742 |
| Sep 3, 2014 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3008876196 | 893756 |
Form 483s FDA has published for this site
- Sep 16, 2022: Form 483 to Athenex Pharma Solutions, LLC, published Nov 14, 2022. fda.gov
- Aug 28, 2019: Form 483 to Athenex Pharma Solutions, LLC, published Nov 12, 2019. fda.gov
- Dec 13, 2017: Form 483 to Athenex Pharma Solutions, LLC, published Jan 28, 2020. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 6 numbered observations in all, across 3 inspections ending Dec 13, 2017 to Sep 16, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Sep 8, 2022 to Sep 16, 2022: 1 observation
- Firm on the cover
- Athenex Pharma Solutions, LLC, 11342 Main St, Clarence, NY 14031 -1718
- FEI number
- 3008876196
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 158-15 Libert y Avenue Jamaica, NY 11433
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, your investigations into sterility failures were not conducted thoroughly to evaluate potential root causes in the production facility and to implement robust corrective and preventative action plans to mitigate sterility risks to products. During Oct 2021 to Dec 2021, two sterility failures were observed on the finished product sterility testing, identified to be Gram Positive Rods (Bacillus licheniformis and Niallia circulans), belonging to Bacillus species of family. Sterility failures were investigated under #OOS-OOT-2021-0044 on 20Oct2021 for 8mg Norepinephrine in 0.9% Sodium Chloride (250mL IV Bag), Lot# <Redacted B4> and #OOS-OOT-2021-0054 on 02Dec2021 for 1 Unit/mL Vasopressin 0.9% Sodium Chloride (50mL), Lot <Redacted B4>. ...
Inspection Aug 19, 2019: 1 observation
- Firm on the cover
- Athenex Pharma Solutions, LLC, 11342 Main St, Clarence, NY 1 4031 -1718
- FEI number
- 3008876196
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Written production and process control procedmes are not fo llowed in the execution of production and process control functions.
Specifically,
A. The firm's SOP No. APS-SOP-0344 "503B Bulle Formulation and Sealing Process" states to wipe down all work surfaces and equipment with a clean room wiped that has thoroughly wetted witb <Redacted B4>. However, on 08/20/2019 during the manufacturing of Norepinephrine lmg/ml, Lot# S1900185, an operator was obse1ved not wiping down all work smfaces and equipment with a clean room wipe that has been thoroughly wetted with <Redacted B4>
B. The firm's SOP No. APS-SOP-0308 "503B Syringe Compounding Aseptic Plj°cess" states to wipe the top seems around the raw syringe container with am (~) cloth. Wipe top of the container <Redacted B4> Wipe bottom of the container( <Redacted B4>making sure to get into crevices. Wipe all four sides of container <Redacted B4> Rotation of the container may be done for better angles to wipe. ...
Inspection Dec 5, 2017 to Dec 13, 2017: 4 observations
- Firm on the cover
- Athenex Pharma Solutions, LLC, 11342 Main St C ITY, STATE, ZIP CODE, COUNTRY Clarence , NY 14031-1718
- FEI number
- 3008876196
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 158-15 Liberty Avenue Jamaica, NY 11433
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Specifically,
On 12/6/ 17, an operator was observed disinfecting Bay <Redacted B4> ISO 5 <Redacted B4> Laminar Flow Hood <Redacted B4> with <Redacted B4> from <Redacted B4>, rather than <Redacted B4> , as outlined in the firm's procedure and performed in the firm's smoke studies. According to the firm's management and procedures, disinfection of the ISO 5 <Redacted B4> Laminar Flow Hood should be conducted by stating in the area <Redacted B4> in a manner that disinfects from the <Redacted B4>
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
On 12/6/17, I observed no environmental monitoring sampling being performed in the ISO 5 area, in Bay <Redacted B4> Laminar Flow Hood <Redacted B4> , where the operator is working, which is in front of the <Redacted B4> . Currently, the firm's media fill validations and environmental monitoring procedure state that <Redacted B4> however, viable monitoring is only performed in the <Redacted B4>
Observation 3
Equipment for adequate control over temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.
Specifically,
Your firrn 's monitored area is not where approved human finished drug products, which are used as the active ingredient in compounding operations, are stored. Currently, your firm only monitors the temperature in the warehouse in the <Redacted B4> however, approved human finished drug product (active ingredient) is located in the <Redacted B4> area of the warehouse across from the <Redacted B4> The firm has not conducted temperature mapping studies in the worst-case conditions, including Summer and Winter, for the current warehouse configuration. Your firm has only done a temperature mapping study in the Spring of the warehouse's current configuration, which showed a broader temperature range for the location where the raw material product is stored than where the temperature probes reside.
Observation 4
The labels of your outsourcing facility's drug products are deficient.
Specifically,
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A), including:
(a) The dosage form.
(b) A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient.
The following list contains examples of labels for drug products which do not contain the required information:
Epinephrine 2mg/250mL in 5% Dexirose
Epinephrine 4mg/250mL in 5% Dextrose
Phenylephrine 10mg/250mL in 0.9% Sodium Chloride
Phenylephrine 20mg/250mL in 0.9% Sodium Chloride
Phenylephrine 25mgl250mL in 0.9% Sodium Chloride
Phenylephrine 40mg/250mL in 0.9% Sodium Chloride
Phenylephrine 50mg/250mL in 0.9% Sodium Chloride
Norepinephrine 8mgl250mL in 0.9% Sodium Chloride
State board of pharmacy records
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- Feb 11, 2019: “Application for consent order granted Penalty agreed upon $20,000 fine, 1 year probation.”, registration 035379, case Cal. No. 30733, ATHENEX PHARMA SOLUTIONS, LLC, CLARENCE, NY. Board list
What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0000050 | Outsourcing Facility-Distributor | Athenex Pharma Solutions, LLC | CLARENCE, NY | Closed |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- New York State Education Department disciplinary records
- Delaware Division of Professional Regulation license file
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.